912-P: Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes

Introduction Boehringer-Ingelheim. K. Marsolo: Research Support; Boehringer-Ingelheim, Amgen Inc., Bayer Inc., Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Seqirus, Genentech, Inc., Pfizer Inc. H.B. Bosworth: Research Support; BeBetter Therapeutics, Boehringer-Ingelheim, Improved Patient Outcomes, ESPERION Therapeutics, Inc., Novo Nordisk, Otsuka America Pharmaceutical, Inc., Sanofi, National Institutes of Health, Veterans Administration, elton john foundation. N. Pagidipati: Research Support; Alnylam Pharmaceuticals, Inc., Amgen Inc., Eli Lilly and Company. Consultant; ESPERION Therapeutics, Inc., AstraZeneca. Research Support; Boehringer-Ingelheim, Novartis AG, Novo Nordisk. Consultant; CRISPR Therapeutics. Research Support; Bayer Inc., Merck Merck Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation. Funding Boehringer Ingelheim